Merck Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Merck Tbk. trades at Rp3,840 (market cap 1.7T, 37.6K 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp248 (market cap 167.37B, 96.7K 24h volume). The key difference: Merck Tbk. is far larger — about 10.2× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (96.7K versus 37.6K). Which is the better fit depends on your goals.
| MERK | OBAT | |
|---|---|---|
Market Cap | 1.7T | 167.37B |
Volume | 37.6K | 96.7K |
Lot | 376 | 967 |
Turnover | 144.47M | 23.82M |
Average Price | 3,842.23 | 246.34 |
Value | 144.47M | 23.82M |
Indicative Equilibrium Price | 3,840 | 248 |
Indicative Equilibrium Volume | 7 | 41 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →